Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 1
---
2024, a majority of the stockholders of the Company approved the proposed reverse stock split. On February
10, 2025, the Board approved a 1-for-5 reverse split ratio. On February 24, 2025, the Company effectuated a 1-for-5 reverse stock split
of our common stock (the “1:5 Reverse Stock Split”). Beginning February 24, 2025, our common stock traded on The Nasdaq Capital
Market on a split adjusted basis. All common share and applicable per share amounts in this Annual Report on Form 10-K have been retroactively
restated to reflect the effect of the 1:5 Reverse Stock Split. 

Previously, at the 2024 Annual Meeting of Stockholders
in July 2024, our stockholders approved an amendment to our Certificate of Incorporation to effect reverse stock split of our common
stock at a range of ratios between 1:5 to 1:12, and on July 19, 2024, our Board approved the implementation of the reverse stock split
at a ratio of 1:12 (the “1:12 Reverse Stock Split”, and together with the 1:5 Reverse Stock Split, the “Reverse Stock
Splits”). On August 12, 2024, we effectuated a 1-for-12 reverse stock split of our common stock. Beginning August 12, 2024, our
common stock began trading on The Nasdaq Capital Market on a split adjusted basis.

The Reverse Stock Splits did not change the authorized
number of shares of common stock or preferred stock. Proportional adjustments were made to the number of shares of common stock issuable
upon exercise or conversion of our equity awards, warrants, and other equity instruments convertible into common stock, as well as the
respective exercise prices, if applicable in accordance with the terms of the instruments. No fractional shares of common stock were
issued in connection with the Reverse Stock Splits and all fractional shares were rounded up to the nearest whole share with respect
to outstanding shares of common stock. Unless otherwise noted, all references to numbers of shares of our common stock and per share
information presented in this Annual Report on Form 10-K have been retroactively adjusted, as appropriate, to reflect the Reverse Stock
Splits.

February
2025 Offering

On
February 5, 2025, we entered into a securities purchase agreement (the “February 2025 Securities Purchase Agreement”)